Synthetic Biologics, Inc.
| NYSE MKT: SYN
Synthetic Biologics, Inc. operates as a biotechnology company, which is focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. It develops product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. The company's products include reaZin, Trimesta, Effirma and wellZin. Its reaZin product is being developed as a prescription medical food for the dietary management of patients with Alzheimer's disease and mild cognitive impairment. The company's Trimesta is a drug candidate, which is being developed for the treatment of relapsing-remitting multiple sclerosis in women. Its Effirma drug candidate is being developed for the treatment of fibromyalgia. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Ann Arbor, MI.